(April 14, 2016, 1:48 PM EDT) -- WASHINGTON, D.C. — An appellate court incorrectly disregarded objective indicia of nonobviousness that clearly apply to the claimed patent invention, a biopharmaceutical company argues in a March 28 petition seeking review by the U.S. Supreme Court of a decision that invalidated four of five patents for an antibiotic (Cubist Pharmaceuticals, Inc. v. Hospira, Inc., No. 15-1210, U.S. Sup.)....